Alirocumab Reduces Absolute CV Risk the Most for Those With Diabetes
Among those receiving alirocumab + statin therapy to reduce the risk for another CE after a recent ACS, absolute risk reduction is greater for those with diabetes.
Metabolic
Neurofilament Light Chain Levels Predict Stroke Risk in Diabetes
Serum neurofilament light chain levels can predict incident stroke among middle-aged and older adults with diabetes mellitus.
High Plasma Lipoprotein(a) Levels Linked to Ischemic Stroke Risk
Elevated lipoprotein(a) and corresponding LPA genotypes are also associated with an increased risk for ischemic stroke, although the incremental risk is less pronounced.
Statin Use Associated With Higher Incidence of Diabetes
There may be a dose-dependent relationship between statin therapy and new-onset diabetes across the duration of statin use.
Adding PCSK9i to Niacin Therapy Reduces Lp(a) Concentrations
Adding proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) to background niacin therapy is shown to reduce lipoprotein(a) [Lp(a)] by approximately 15%, according to study results published in the Journal of Clinical Lipidology. In this study, 150 patients were divided into 2 groups: 136 received PCSK9i monotherapy and 14 received PCSK9i and niacin combination therapy. PCSK9i…
Suboptimal Use of Secondary Prevention Therapies in Atherosclerotic CVD
Glucose-lowering medications and high-intensity statins are not being used sufficiently among high-risk individuals with atherosclerotic cardiovascular disease and diabetes.
Newer Glucose-Lowering Medications Should Be Used for T2D With CVD
Risk for MACE was comparable between the 2 trial types in the meta-analysis.
CV Benefits of Lipoprotein(a) Reduction With PCSK9 Inhibitors
Investigators evaluated whether lower on-study and greater percentage reductions in lipoprotein(a) are associated with a lower risk for major adverse cardiovascular events.
Evolocumab Safe and Effective for Individuals With Type 2 Diabetes
The BANTING study provides additional evidence about the efficacy and safety of evolocumab in individuals with T2D and hypercholesterolemia.
Lipid-Lowering Effects of Turmeric, Curcuminoids Examined
Findings of a recently published systematic review and meta-analysis revealed that turmeric and curcuminoids can significantly alter blood lipid levels in patients with metabolic diseases.
Next post in Dyslipidemia
